Nevertheless, Nrf2 activators such as dimethyl fumarate are currently used to treat multiple sclerosis [69,70] and new trials are exploring the safety and tolerability of the bardoxolone methyl formulation RTA 402 [23]. The gene discussed is NFE2L2; the disease is multiple sclerosis.